First Time Loading...

Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 95.56 USD 0.43% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. [ Read More ]

The intrinsic value of one EW stock under the Base Case scenario is 62.27 USD. Compared to the current market price of 95.56 USD, Edwards Lifesciences Corp is Overvalued by 35%.

Key Points:
EW Intrinsic Value
Base Case
62.27 USD
Overvaluation 35%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Edwards Lifesciences Corp

Backtest EW Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EW stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Company Aims to Boost Full-Year TMTT Sales
2023-Q4 Earnings Call

Company Aims to Boost Full-Year TMTT Sales

The company expressed optimism with forecasts, expecting full-year TMTT sales to hit the higher end of the $280 million - $320 million guidance. For Q1, anticipated sales are between $1.53 billion and $1.61 billion, with adjusted EPS of $0.62 to $0.66. Margins dipped to 76.8% versus last year's 81% due to exchange rate impacts, but the adjusted gross profit margin is anticipated to stabilize between 76% and 78% in 2024. Investments in transcatheter personnel and patient activation initiatives increased SG&A to $480 million (31.3% of sales), targeting 29-30% for the full year. R&D spending rose by 16% to $270 million, aiming for 17-18% of 2024 sales. Free cash flow for Q4 was $48 million, with adjusted free cash flow in 2023 at $943 million, excluding a $300 million payment. For 2024, free cash flow is projected to grow between $1.1 billion and $1.4 billion.

Financials

Balance Sheet Decomposition
Edwards Lifesciences Corp

Current Assets 4B
Cash & Short-Term Investments 1.6B
Receivables 836.9m
Other Current Assets 1.6B
Non-Current Assets 5.3B
Long-Term Investments 583.9m
PP&E 1.8B
Intangibles 1.7B
Other Non-Current Assets 1.2B
Current Liabilities 1.2B
Accounts Payable 1.4B
Accrued Liabilities 819.7m
Other Current Liabilities -996.2m
Non-Current Liabilities 1.5B
Long-Term Debt 597m
Other Non-Current Liabilities 920.8m
Efficiency

Earnings Waterfall
Edwards Lifesciences Corp

Revenue
6B USD
Cost of Revenue
-1.4B USD
Gross Profit
4.6B USD
Operating Expenses
-2.9B USD
Operating Income
1.8B USD
Other Expenses
-352.4m USD
Net Income
1.4B USD

Free Cash Flow Analysis
Edwards Lifesciences Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

EW Profitability Score
Profitability Due Diligence

Edwards Lifesciences Corp's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROE
Positive 3-Year Average ROIC
70/100
Profitability
Score

Edwards Lifesciences Corp's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

EW Solvency Score
Solvency Due Diligence

Edwards Lifesciences Corp's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
94/100
Solvency
Score

Edwards Lifesciences Corp's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EW Price Targets Summary
Edwards Lifesciences Corp

Wall Street analysts forecast EW stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EW is 93.6 USD with a low forecast of 72.72 USD and a high forecast of 110.25 USD.

Lowest
Price Target
72.72 USD
24% Downside
Average
Price Target
93.6 USD
2% Downside
Highest
Price Target
110.25 USD
15% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EW Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EW Price
Edwards Lifesciences Corp

1M 1M
+13%
6M 6M
+38%
1Y 1Y
+17%
3Y 3Y
+16%
5Y 5Y
+50%
10Y 10Y
+673%
Annual Price Range
95.56
52w Low
61.71
52w High
95.56
Price Metrics
Average Annual Return 9.61%
Standard Deviation of Annual Returns 36.74%
Max Drawdown -53%
Shares Statistics
Market Capitalization 57.4B USD
Shares Outstanding 609 000 000
Percentage of Shares Shorted 1.42%

EW Return Decomposition
Main factors of price return

What is price return decomposition?

EW News

Other Videos

Company Profile

Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp

Country

United States of America

Industry

Health Care

Market Cap

57.4B USD

Dividend Yield

0%

Description

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,700 full-time employees. The company went IPO on 2000-03-27. The firm is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. The company also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.

Contact

CALIFORNIA
Irvine
1 Edwards Way
+19492502500.0
https://www.edwards.com

IPO

2000-03-27

Employees

15 700

Officers

CEO & Director
Mr. Bernard J. Zovighian
Corporate VP & CFO
Mr. Scott B. Ullem
Corporate VP and Group President of TAVR & Surgical Structural Heart
Mr. Larry L. Wood
Corporate Vice President of Japan, Asia Pacific & Greater China
Mr. Jean-Luc Lemercier
Corporate VP of Advanced Technology & Chief Scientific Officer
Dr. Todd J. Brinton FACC, M.D.
Vice President of Investor Relations
Mark Wilterding
Show More
Corporate VP & General Counsel
Mr. Arnold A. Pinkston
Corporate Vice President of Public Affairs
Mr. Dirksen J. Lehman
Corporate Vice President of Strategy & Corporate Development
Mr. Donald E. Bobo Jr.
Corporate Vice President of Human Resources
Ms. Christine Z. McCauley
Show Less

See Also

Discover More
What is the Intrinsic Value of one EW stock?

The intrinsic value of one EW stock under the Base Case scenario is 62.27 USD.

Is EW stock undervalued or overvalued?

Compared to the current market price of 95.56 USD, Edwards Lifesciences Corp is Overvalued by 35%.